Frontage provides comprehensive clinical trial support to ensure rapid start-up and execution of your programs. With 25+ years of experience, we deliver services ranging from study conduct to data reporting and preparation of final reports, suitable for FDA submission.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
In this Q&A, Nan Zhang MD PhD, Vice President of Global Central Lab and Biomarker Services at Frontage, speaks on the role of analytical and central laboratories in providing accurate laboratory data and seamless logistics services.
In this case study, we share how Frontage used Gyrolab to conduct a Sponsor's study efficiently saving precious sample volumes.
In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical. The important question has been how to translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified. Dr. Nan Zhang, VP of Global Central Lab Services at Frontage Laboratories Inc., will provide a valuable update on the application of Tissue IHC in new biomarker development, selection between different types of IHC, and validation of the methodology to be used for patient testing in clinical trials.